Menu
Not yet recruiting NCT06026696

Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière

— Observational Ischemic Stroke Hemorrhagic Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: follow-up.
Who it may be relevant to
Registry conditions: Ischemic Stroke, Hemorrhagic Stroke. Basic parameters: 18 years — 100 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Cohorte de Maladies Neurovasculaires Prises en Charge à la Phase aiguë et Suivies à Lariboisière

Overview

Neurovascular diseases can cause ischaemic or haemorrhagic strokes. While the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. What's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. Patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the Lariboisière neurovascular intensive care unit (USINV) could provide a particularly rich resource.

Interventions

  • Other follow-up
    Long term follow-up

Primary outcome measures

  • Incidence of a vascular event [Time frame: Up to 5 years]
Secondary outcome measures (12)
  • Incidence of a vascular event [Time frame: Up to 10 years]
  • Modified Rankin score [Time frame: At 3 months]
  • Modified Rankin score [Time frame: At 1 year]
  • Modified Rankin score [Time frame: At 2 years]
  • Modified Rankin score [Time frame: At 3 years]
  • Modified Rankin score [Time frame: At 4 years]
  • Modified Rankin score [Time frame: At 5 years]
  • Modified Rankin score [Time frame: At 6 years]
  • Modified Rankin score [Time frame: At 7 years]
  • Modified Rankin score [Time frame: At 8 years]
  • Modified Rankin score [Time frame: At 9 years]
  • Modified Rankin score [Time frame: At 10 years]

Eligibility criteria

Inclusion criteria

  • Adult patients ≥18 years
  • Patients admitted to the Neurovascular Intensive Care Unit with acute cerebrovascular disease OR Patients managed for acute cerebrovascular pathology with or without stroke by the Lariboisière neurology team.
  • No opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative.

Exclusion criteria

  • Patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship
  • Patient suffering from a rare neurovascular disease and being followed at the "Centre de référence des maladies vasculaires rares du cerveau et de l'oeil" (CERVCO)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06026696 · APHP221076

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗